CSIMarket Company Name, Ticker, Competitors, else..


Regeneron Pharmaceuticals Inc   (REGN)
Other Ticker:  
 

Regeneron Pharmaceuticals Inc

REGN's Fundamental analysis



Looking into Regeneron Pharmaceuticals Inc growth rates, revenue grew by 12.32 % in II. Quarter 2024 from the same quarter a year ago. Ranking at No. 862

Major Pharmaceutical Preparations industry recorded growth of revenues by 5.17 %

Regeneron Pharmaceuticals Inc 's net income grew by 47.9 % in II. Quarter 2024 year on year, above company average,

• More on REGN's Growth


Regeneron Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Regeneron Pharmaceuticals Inc realized cash reduction of $ -0.19 per share in trailing twelve-month period.
Company
26.92
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.69.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.77.


• More on REGN's Valuation
 
 Total Debt (Millions $) 1,984
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,002,907
 Net Income/Employee (TTM) $ 321,316
 Receivable Turnover (TTM) 2.43
 Tangible Book Value (Per Share $) 234.87

Regeneron Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Regeneron Pharmaceuticals Inc realized cash outflow of $ -0.19per share in trailing twelve-month period.
Company
26.92
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.69.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.77.

Regeneron Pharmaceuticals Inc Price to Book Ratio is at 4.16 lower than Industry Avg. of 85.07. and higher than S&P 500 Avg. of 0

• More on REGN's Valuation

•  Market Capitalization (Millions $) 117,208
•  Shares Outstanding (Millions) 115
•  Employees 13,450
•  Revenues (TTM) (Millions $) 13,489
•  Net Income (TTM) (Millions $) 4,322
•  Cash Flow (TTM) (Millions $) -22
•  Capital Exp. (TTM) (Millions $) -742
•  Total Debt (Millions $) 1,984
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,002,907
•  Net Income/Employee(TTM) $ 321,316
•  Receivable Turnover Ratio (TTM) 2.43
•  Tangible Book Value (Per Share $) 234.87

•  Market Capitalization (Millions $) 117,208
•  Shares Outstanding (Millions) 115
•  Employees 13,450
•  Revenues (TTM) (Millions $) 13,489
•  Net Income (TTM) (Millions $) 4,322
•  Cash Flow (TTM) (Millions $) -22
•  Capital Exp. (TTM) (Millions $) -742


    REGN's Profitability Comparisons
Regeneron Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2024 to 30.15 % from 23.89 % in I. Quarter.

Regeneron Pharmaceuticals Inc net profit margin of 40.38 % is currently ranking no. 12 in Major Pharmaceutical Preparations industry, ranking no. 22 in Healthcare sector and number 176 in S&P 500.


Profitability by Segment
Total 40.38 %



  Ratio
•   Capital Ratio (MRQ) 6.53
•  Total Debt to Equity (MRQ) 0.07
•  Tangible Leverage Ratio (MRQ) 0.24
•  Asset Turnover Ratio (TTM) 0.43
•  Inventory Turnover Ratio (TTM) 0.38



Regeneron Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2024 to 30.15 % from 23.89 % in I. Quarter.

Regeneron Pharmaceuticals Inc net profit margin of 40.38 % is currently ranking no. 12 in Major Pharmaceutical Preparations industry, ranking no. 22 in Healthcare sector and number 176 in S&P 500.

• More on REGN's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com